Literature DB >> 4033804

An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system.

D Clark, G Engberg, E Pileblad, T H Svensson, A Carlsson, A S Freeman, B S Bunney.   

Abstract

Extracellular single unit recording and microiontophoretic studies were carried out in chloral hydrate-anesthetized gallamine-paralyzed rats to investigate the actions of the enantiomers of the dopamine (DA) analogue 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, on the nigrostriatal DA system. Intravenously administered (+)- or (-)-3-PPP consistently inhibited nigral DA neuronal activity; these actions were readily antagonized by haloperidol but were not affected by a pretreatment of reserpine plus alpha-methyltyrosine. In contrast to (+)-3-PPP, the (-)-enantiomer produced only partial inhibition of the majority of cells studied and was also capable of partially reversing the inhibitory action of apomorphine. A prior hemitransection of the brain did not alter the inhibitory action of either enantiomer. Whereas iontophoretically ejected (+)-3-PPP consistently reduced DA cell firing rate, similarly applied (-)-3-PPP reduced the activity of only some DA cells, while the majority were not influenced. In addition, iontophoresis of (-)-3-PPP could reduce the inhibitory effect of similarly applied DA or (+)-3-PPP. The (+)-enantiomer reduced caudate neuronal activity both after intravenous administration and iontophoresis. Intravenously administered (-)-3-PPP failed to influence or increased the activity of these neurons and reversed the inhibitory action of apomorphine. However, iontophoretically ejected drug reduced caudate cell activity and did not influence the inhibitory action of DA. The activity of non-DA zona reticulata neurons was inconsistently influenced by the 3-PPP enantiomers. It is concluded that (+)-3-PPP is a directly acting DA agonist, stimulating both DA autoreceptors and postsynaptic DA receptors. In contrast, (-)-3-PPP appears to be a partial agonist at nigral DA autoreceptors, whereas the action of the drug at putative postsynaptic DA receptors in the caudate remains to clarified.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4033804     DOI: 10.1007/bf00496366

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  43 in total

1.  Electrophysiological evidence for involvement of cyclic adenosine monophosphate in dopamine responses of caudate neurons.

Authors:  G R Siggins; B J Hoffer; U Ungerstedt
Journal:  Life Sci       Date:  1974-08-15       Impact factor: 5.037

2.  The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay.

Authors:  C V Atack
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

3.  Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity.

Authors:  J Arnt; A V Christensen; J Hyttel; J J Larsen; O Svendsen
Journal:  Eur J Pharmacol       Date:  1982-12-24       Impact factor: 4.432

4.  Micromethods in neuropharmacology: an approach to the study of anesthetics.

Authors:  G C Salmoiraghi; F Weight
Journal:  Anesthesiology       Date:  1967 Jan-Feb       Impact factor: 7.892

Review 5.  Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

Review 6.  Effect of apomorphine on schizophrenic symptoms.

Authors:  R C Smith; C Tamminga; J M Davis
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

7.  Dopamine"autoreceptors": pharmacological characterization by microiontophoretic single cell recording studies.

Authors:  G K Aghajanian; B S Bunney
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-03       Impact factor: 3.000

8.  Differential effects of the stereoisomers of 3PPP on dopaminergic and cholinergic neurotransmission in superfused slices of the corpus striatum.

Authors:  S Arbilla; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-08       Impact factor: 3.000

9.  Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.

Authors:  G E Martin; D R Haubrich; M Williams
Journal:  Eur J Pharmacol       Date:  1981-11-19       Impact factor: 4.432

10.  The effects of SCH 23390, YM 09151-2, (+)- and (-)-3-PPP and some classical neuroleptics on D-1 and D-2 receptors in rat neostriatum in vitro.

Authors:  J F Plantjé; H A Hansen; F J Daus; J C Stoof
Journal:  Eur J Pharmacol       Date:  1984-10-01       Impact factor: 4.432

View more
  12 in total

1.  Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

Authors:  K Svensson; A Ekman; M F Piercey; W E Hoffmann; J T Lum; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

2.  Behavioural profile of partial D2 dopamine receptor agonists. 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy.

Authors:  D Clark; L J Furmidge; N Petry; Z Y Tong; M Ericsson; D Johnson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 3.  Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry.

Authors:  G Debonnel
Journal:  J Psychiatry Neurosci       Date:  1993-07       Impact factor: 6.186

Review 4.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

5.  Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

Authors:  S Hjorth; K Svensson; A Carlsson; H Wikström; B Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

6.  Differential effects of 3-PPP enantiomers on extracellular dopamine concentration in the caudate-putamen and nucleus accumbens of rats.

Authors:  R E See
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

7.  On the mode of action of six putative dopamine receptor agonists on suppression of exploratory behaviour in rats.

Authors:  L Ståhle; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Modulation by sigma ligands of N-methyl-D-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency.

Authors:  F P Monnet; P Blier; G Debonnel; C de Montigny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

9.  NSD 1034: an amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors.

Authors:  H Nissbrandt; G Engberg; H Wikström; T Magnusson; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

10.  GBR 13098, a selective dopamine uptake inhibitor; behavioural, biochemical and electrophysiological studies.

Authors:  E Pileblad; G Engberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.